ArticleFrontiers in oncology2021

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

SiNi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.